Anti-Hepatitis B Virus Activity of ORI-9020, a Novel Phosphorothioate Dinucleotide, in a Transgenic Mouse Model

Authors

R. P. Iyer
A. Roland
Y. Jin
S. Mounir
B. Korba
Justin G. Julander, Utah State UniversityFollow
John D. Morrey, Utah State UniversityFollow

Document Type

Article

Journal/Book Title/Conference

Antimicrobial Agents and Chemotherapy

Volume

48

Issue

6

Publisher

American Society for Microbiology

Publication Date

2004

First Page

2318

Last Page

2320

Abstract

ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P < = 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.

Comments

Originally published by the American Society for Microbiology. Publisher's PDF and HTML fulltext available through remote link.

Recommended Citation

Iyer, R.P., A. Roland, Y. Jin, S. Mounir, B. Korba, J.G. Julander, and J.D. Morrey 2004. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model Antimicrobial Agents and Chemotherapy 48(6): 2318-2320.